GB0000313D0 - Formulation - Google Patents

Formulation

Info

Publication number
GB0000313D0
GB0000313D0 GBGB0000313.7A GB0000313A GB0000313D0 GB 0000313 D0 GB0000313 D0 GB 0000313D0 GB 0000313 A GB0000313 A GB 0000313A GB 0000313 D0 GB0000313 D0 GB 0000313D0
Authority
GB
United Kingdom
Prior art keywords
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0000313.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0000313(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to GBGB0000313.7A priority Critical patent/GB0000313D0/en
Publication of GB0000313D0 publication Critical patent/GB0000313D0/en
Priority to GBGB0008837.7A priority patent/GB0008837D0/en
Priority to BRPI0107445-8A priority patent/BR0107445B1/pt
Priority to PCT/GB2001/000049 priority patent/WO2001051056A1/en
Priority to SI200130446T priority patent/SI1250138T2/sl
Priority to RU2002121507A priority patent/RU2263507C9/ru
Priority to HK03105241.3A priority patent/HK1052884B/zh
Priority to DK01900186.6T priority patent/DK1250138T4/en
Priority to AT01900186T priority patent/ATE306928T1/de
Priority to HK03101532.0A priority patent/HK1049286B/en
Priority to EEP200200387A priority patent/EE05421B1/xx
Priority to CNB018035469A priority patent/CN1222292C/zh
Priority to MXPA02006698A priority patent/MXPA02006698A/es
Priority to EP05016921A priority patent/EP1669073A3/en
Priority to SI200131044T priority patent/SI2266573T1/sl
Priority to JP2001551480A priority patent/JP3713237B2/ja
Priority to DK10180667.7T priority patent/DK2266573T3/en
Priority to EP10180661.0A priority patent/EP2286818B1/en
Priority to AU23863/01A priority patent/AU762080B2/en
Priority to PL356030A priority patent/PL202525B1/pl
Priority to KR1020027008855A priority patent/KR100802366B1/ko
Priority to HU0204137A priority patent/HU230162B1/hu
Priority to GB0100407A priority patent/GB2359254B/en
Priority to PT101806677T priority patent/PT2266573E/pt
Priority to EG20010017A priority patent/EG24074A/xx
Priority to DE60114145.8T priority patent/DE60114145T3/de
Priority to EP10180667.7A priority patent/EP2266573B1/en
Priority to EP01900186.6A priority patent/EP1250138B2/en
Priority to SK984-2002A priority patent/SK287221B6/sk
Priority to ES10180667.7T priority patent/ES2543384T3/es
Priority to ES01900186.6T priority patent/ES2248272T5/es
Priority to CZ2002-2384A priority patent/CZ304689B6/cs
Priority to IL15023001A priority patent/IL150230A0/xx
Priority to US10/169,777 priority patent/US20030125387A1/en
Priority to CA002351004A priority patent/CA2351004C/en
Priority to US09/756,291 priority patent/US6774122B2/en
Priority to PT102548A priority patent/PT102548A/pt
Priority to IT000005A priority patent/ITTO20010005A1/it
Priority to BE2001/0021A priority patent/BE1013477A3/fr
Priority to IT2001TO000008A priority patent/ITTO20010008A1/it
Priority to MYPI20010107A priority patent/MY118583A/en
Priority to ARP010100100A priority patent/AR027510A1/es
Priority to FR0100248A priority patent/FR2803516B1/fr
Priority to CO01001317A priority patent/CO5280206A1/es
Priority to CH00029/01A priority patent/CH696260A5/de
Priority to DE10100779A priority patent/DE10100779A1/de
Priority to ES200100057A priority patent/ES2186517B2/es
Priority to TW090100514A priority patent/TWI259086B/zh
Priority to NL1017075A priority patent/NL1017075C2/nl
Priority to UA2002086628A priority patent/UA75879C2/uk
Priority to ZA200204165A priority patent/ZA200204165B/xx
Priority to IL150230A priority patent/IL150230A/en
Priority to BG106833A priority patent/BG65776B1/bg
Priority to NO20023227A priority patent/NO336286B1/no
Priority to IS6454A priority patent/IS2932B/is
Priority to JP2003362875A priority patent/JP2004107353A/ja
Priority to US10/872,784 priority patent/US7456160B2/en
Priority to US12/285,887 priority patent/US8329680B2/en
Priority to HK11103860.8A priority patent/HK1150021B/en
Priority to JP2011135962A priority patent/JP2011190275A/ja
Priority to US13/602,667 priority patent/US8466139B2/en
Priority to NO20150741A priority patent/NO337329B1/no
Priority to CY20151100648T priority patent/CY1116520T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0000313.7A 2000-01-10 2000-01-10 Formulation Ceased GB0000313D0 (en)

Priority Applications (63)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
BRPI0107445-8A BR0107445B1 (pt) 2000-01-10 2001-01-08 formulação farmacêutica, e, uso de fulvestrante na preparação de uma formulação farmacêutica.
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
SI200130446T SI1250138T2 (sl) 2000-01-10 2001-01-08 Formulacije fulvestranta
RU2002121507A RU2263507C9 (ru) 2000-01-10 2001-01-08 Композиция фульвестранта
HK03105241.3A HK1052884B (zh) 2000-01-10 2001-01-08 氟维司群制剂
DK01900186.6T DK1250138T4 (en) 2000-01-10 2001-01-08 Fulvestrantformulering
AT01900186T ATE306928T1 (de) 2000-01-10 2001-01-08 Fulvestrant formulierung
HK03101532.0A HK1049286B (en) 2000-01-10 2001-01-08 Fulvestrant formulation
EEP200200387A EE05421B1 (et) 2000-01-10 2001-01-08 Fulvestrandi formulatsioonid
CNB018035469A CN1222292C (zh) 2000-01-10 2001-01-08 氟维司群制剂
MXPA02006698A MXPA02006698A (es) 2000-01-10 2001-01-08 Formulacion de fulvestrant.
EP05016921A EP1669073A3 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
SI200131044T SI2266573T1 (sl) 2000-01-10 2001-01-08 Formulacija fulvestranta
JP2001551480A JP3713237B2 (ja) 2000-01-10 2001-01-08 フルベストラント製剤
DK10180667.7T DK2266573T3 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
EP10180661.0A EP2286818B1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
AU23863/01A AU762080B2 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
PL356030A PL202525B1 (pl) 2000-01-10 2001-01-08 Preparat farmaceutyczny fulwestrantu
KR1020027008855A KR100802366B1 (ko) 2000-01-10 2001-01-08 풀베스트란트 제제
HU0204137A HU230162B1 (hu) 2000-01-10 2001-01-08 Fulvesztrantot tartalmazó gyógyászati készítmény
GB0100407A GB2359254B (en) 2000-01-10 2001-01-08 Formulation
PT101806677T PT2266573E (pt) 2000-01-10 2001-01-08 Formulação de fulvestrant
EG20010017A EG24074A (en) 2000-01-10 2001-01-08 Formulation
DE60114145.8T DE60114145T3 (de) 2000-01-10 2001-01-08 Fulvestrant formulierung
EP10180667.7A EP2266573B1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
EP01900186.6A EP1250138B2 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
SK984-2002A SK287221B6 (sk) 2000-01-10 2001-01-08 Farmaceutická formulácia obsahujúca fulvestrant
ES10180667.7T ES2543384T3 (es) 2000-01-10 2001-01-08 Formulación de fulvestrant
ES01900186.6T ES2248272T5 (es) 2000-01-10 2001-01-08 Formulación de fulvestrant
CZ2002-2384A CZ304689B6 (cs) 2000-01-10 2001-01-08 Farmaceutický přípravek obsahující fulvestrant a jeho použití pro výrobu léčiva
IL15023001A IL150230A0 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
US10/169,777 US20030125387A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
CA002351004A CA2351004C (en) 2000-01-10 2001-01-08 Formulation
US09/756,291 US6774122B2 (en) 2000-01-10 2001-01-09 Formulation
PT102548A PT102548A (pt) 2000-01-10 2001-01-09 Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)
IT000005A ITTO20010005A1 (it) 2000-01-10 2001-01-09 Formulazione farmaceutica.
BE2001/0021A BE1013477A3 (fr) 2000-01-10 2001-01-09 Formulation.
IT2001TO000008A ITTO20010008A1 (it) 2000-01-10 2001-01-10 Formulazione farmaceutica
MYPI20010107A MY118583A (en) 2000-01-10 2001-01-10 Formulation
ARP010100100A AR027510A1 (es) 2000-01-10 2001-01-10 Formulacion
FR0100248A FR2803516B1 (fr) 2000-01-10 2001-01-10 Formulation injectable de fulvestrant
CO01001317A CO5280206A1 (es) 2000-01-10 2001-01-10 Formulacion farmaceutica de liberacion sostenida adaptada para administracion por inyeccion
CH00029/01A CH696260A5 (de) 2000-01-10 2001-01-10 Fulvestrant Formulierung.
DE10100779A DE10100779A1 (de) 2000-01-10 2001-01-10 Formulierung
ES200100057A ES2186517B2 (es) 2000-01-10 2001-01-10 Formulacion farmaceutica que contiene fulvestrant.
TW090100514A TWI259086B (en) 2000-01-10 2001-01-10 Pharmaceutical formulation adapted for intra-muscular injection
NL1017075A NL1017075C2 (nl) 2000-01-10 2001-01-10 Preparaat.
UA2002086628A UA75879C2 (en) 2000-01-10 2001-08-01 Fulvestrant composition (variants)
ZA200204165A ZA200204165B (en) 2000-01-10 2002-05-24 Fulvestrant formulation.
IL150230A IL150230A (en) 2000-01-10 2002-06-13 Formulation of Fulvestrant
BG106833A BG65776B1 (bg) 2000-01-10 2002-06-18 Фулвестрантов състав
NO20023227A NO336286B1 (no) 2000-01-10 2002-07-03 Fulvestrant-formulering og sprøyte eller glassbeholder inneholdende samme
IS6454A IS2932B (is) 2000-01-10 2002-07-03 Fúlvestrant samsetning
JP2003362875A JP2004107353A (ja) 2000-01-10 2003-10-23 フルベストラント製剤
US10/872,784 US7456160B2 (en) 2000-01-10 2004-06-22 Formulation
US12/285,887 US8329680B2 (en) 2000-01-10 2008-10-15 Formulation
HK11103860.8A HK1150021B (en) 2000-01-10 2011-04-18 Fulvestrant formulation
JP2011135962A JP2011190275A (ja) 2000-01-10 2011-06-20 フルベストラント製剤
US13/602,667 US8466139B2 (en) 2000-01-10 2012-09-04 Formulation
NO20150741A NO337329B1 (no) 2000-01-10 2015-06-08 Anvendelse av fulvestrant-formulering for behandling av brystkreft
CY20151100648T CY1116520T1 (el) 2000-01-10 2015-07-22 Φαρμακοτεχνικη μορφη fulvestrant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation

Publications (1)

Publication Number Publication Date
GB0000313D0 true GB0000313D0 (en) 2000-03-01

Family

ID=26243352

Family Applications (3)

Application Number Title Priority Date Filing Date
GBGB0000313.7A Ceased GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A Ceased GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
GB0100407A Expired - Lifetime GB2359254B (en) 2000-01-10 2001-01-08 Formulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
GBGB0008837.7A Ceased GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
GB0100407A Expired - Lifetime GB2359254B (en) 2000-01-10 2001-01-08 Formulation

Country Status (41)

Country Link
US (5) US20030125387A1 (enExample)
EP (4) EP2286818B1 (enExample)
JP (3) JP3713237B2 (enExample)
KR (1) KR100802366B1 (enExample)
CN (1) CN1222292C (enExample)
AR (1) AR027510A1 (enExample)
AT (1) ATE306928T1 (enExample)
AU (1) AU762080B2 (enExample)
BE (1) BE1013477A3 (enExample)
BG (1) BG65776B1 (enExample)
BR (1) BR0107445B1 (enExample)
CA (1) CA2351004C (enExample)
CH (1) CH696260A5 (enExample)
CO (1) CO5280206A1 (enExample)
CY (1) CY1116520T1 (enExample)
CZ (1) CZ304689B6 (enExample)
DE (2) DE60114145T3 (enExample)
DK (2) DK1250138T4 (enExample)
EE (1) EE05421B1 (enExample)
EG (1) EG24074A (enExample)
ES (3) ES2248272T5 (enExample)
FR (1) FR2803516B1 (enExample)
GB (3) GB0000313D0 (enExample)
HK (2) HK1052884B (enExample)
HU (1) HU230162B1 (enExample)
IL (2) IL150230A0 (enExample)
IS (1) IS2932B (enExample)
IT (2) ITTO20010005A1 (enExample)
MX (1) MXPA02006698A (enExample)
MY (1) MY118583A (enExample)
NL (1) NL1017075C2 (enExample)
NO (2) NO336286B1 (enExample)
PL (1) PL202525B1 (enExample)
PT (2) PT2266573E (enExample)
RU (1) RU2263507C9 (enExample)
SI (2) SI2266573T1 (enExample)
SK (1) SK287221B6 (enExample)
TW (1) TWI259086B (enExample)
UA (1) UA75879C2 (enExample)
WO (1) WO2001051056A1 (enExample)
ZA (1) ZA200204165B (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
HUP0400115A3 (en) * 2001-07-07 2005-11-28 Astrazeneca Ab Pharmaceutical composition for the intramuscular administration of fulvestrant
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
BRPI0608777A2 (pt) * 2005-04-15 2010-01-26 Schering Corp métodos para tratamento ou prevenção de cáncer, bem como uso de inibidores de igf1r na preparação de composições farmacêuticas
KR20080066926A (ko) * 2005-09-26 2008-07-17 호스피라 오스트레일리아 피티와이 리미티드 풀베스트란트 제형
RU2338538C1 (ru) * 2007-02-09 2008-11-20 Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова Антигипотензивное средство
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
MX2012014431A (es) 2010-06-10 2013-02-26 Aragon Pharmaceuticals Inc Modulares del receptor de estrogenos y usos de los mismos.
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2616078B1 (en) * 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX357496B (es) 2011-12-14 2018-07-11 Seragon Pharmaceuticals Inc Moduladores del receptor de estrógenos fluorados y sus usos.
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
ES2983451T3 (es) * 2012-04-09 2024-10-23 Eagle Pharmaceuticals Inc Formulaciones de Fulvestrant
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014169462A1 (zh) 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
EP3041512A4 (en) * 2013-09-06 2017-05-10 Ahmed, Salah U. Fulvestrant compositions
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
EP3116497A2 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
NZ769496A (en) 2014-12-18 2023-09-29 Hoffmann La Roche Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
IL310489A (en) 2015-10-01 2024-03-01 Olema Pharmaceuticals Inc TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS AND COMPOSITIONS COMPRISING SAME FOR USE IN TREATING CANCER
US20180289721A1 (en) 2015-10-13 2018-10-11 Themis Medicare Limited Fulvestrant compositions
HRP20221462T1 (hr) 2015-12-09 2023-01-20 The Board Of Trustees Of The University Of Illinois Selektivni nishodni regulatori receptora estrogena na bazi benzotiofena
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP6682163B2 (ja) * 2016-04-06 2020-04-15 富士フイルム株式会社 医薬組成物
US9969732B2 (en) 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP6611932B2 (ja) * 2016-05-31 2019-11-27 富士フイルム株式会社 医薬組成物
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
US20170362228A1 (en) 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
KR102670293B1 (ko) 2017-11-08 2024-05-30 이글 파마슈티컬즈 인코포레이티드 풀베스트란트 제제 및 그의 사용 방법
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
EP3801553A4 (en) 2018-05-24 2022-04-27 Kashiv Biosciences, LLC PRODRUGS OF FULVESTRANT
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
BR112021008516A2 (pt) 2018-11-01 2021-09-14 Syros Pharmaceuticals, Inc. Inibidores de quinase 7 dependente de ciclina (cdk 7)
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
US12201591B2 (en) 2019-07-03 2025-01-21 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
MX2022000279A (es) 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
EP4074304A4 (en) * 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
PE20240225A1 (es) 2020-11-24 2024-02-16 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos
AU2022218128A1 (en) 2021-02-02 2023-08-17 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
KR20230094172A (ko) * 2021-12-20 2023-06-27 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EP4525925A1 (en) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2024189481A1 (en) 2023-03-10 2024-09-19 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (enExample) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0310542B1 (de) † 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
GB8813353D0 (en) † 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
KR980008226A (ko) 1996-07-05 1998-04-30 다케다 쿠니오 시각기능장애의 예방 및 치료제
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
HRP20000366B1 (en) 1997-12-03 2009-08-31 Merck & Co. Inc. Long acting injectable formulations containing hydrogenated castor oil
AU777572B2 (en) 1999-04-01 2004-10-21 Board Of Regents, The University Of Texas System Compositions and methods for treating lymphoma
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
HUP0400115A3 (en) 2001-07-07 2005-11-28 Astrazeneca Ab Pharmaceutical composition for the intramuscular administration of fulvestrant
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
BR0107445B1 (pt) 2012-10-30
EE200200387A (et) 2003-10-15
NO20023227L (no) 2002-07-03
GB0008837D0 (en) 2000-05-31
RU2263507C9 (ru) 2020-07-28
HU230162B1 (hu) 2015-09-28
MY118583A (en) 2004-12-31
JP2003519659A (ja) 2003-06-24
SI1250138T2 (sl) 2015-09-30
SK287221B6 (sk) 2010-03-08
EP2266573B1 (en) 2015-06-17
US20010020016A1 (en) 2001-09-06
CN1394141A (zh) 2003-01-29
HK1052884B (zh) 2006-07-14
GB2359254A (en) 2001-08-22
BR0107445A (pt) 2002-09-17
IS6454A (is) 2002-07-03
DK1250138T3 (da) 2006-01-23
HK1049286A1 (en) 2003-05-09
US6774122B2 (en) 2004-08-10
CA2351004A1 (en) 2001-07-10
NL1017075A1 (nl) 2001-07-11
US20120329766A1 (en) 2012-12-27
US8466139B2 (en) 2013-06-18
DK2266573T3 (en) 2015-07-20
SK9842002A3 (en) 2003-05-02
KR100802366B1 (ko) 2008-02-13
EP1250138B2 (en) 2015-07-08
ES2186517A1 (es) 2003-05-01
SI1250138T1 (sl) 2006-02-28
ATE306928T1 (de) 2005-11-15
ITTO20010005A1 (it) 2001-07-11
EG24074A (en) 2008-05-11
GB2359254B (en) 2002-06-19
FR2803516A1 (fr) 2001-07-13
HUP0204137A3 (en) 2005-03-29
WO2001051056A1 (en) 2001-07-19
ES2248272T3 (es) 2006-03-16
JP2011190275A (ja) 2011-09-29
KR20020073499A (ko) 2002-09-26
US20030125387A1 (en) 2003-07-03
BG106833A (en) 2003-03-31
EP2266573A1 (en) 2010-12-29
RU2002121507A (ru) 2004-03-20
ES2186517B2 (es) 2004-03-16
US7456160B2 (en) 2008-11-25
AU762080B2 (en) 2003-06-19
DE60114145T3 (de) 2015-09-17
BG65776B1 (bg) 2009-11-30
ZA200204165B (en) 2003-10-29
PL356030A1 (en) 2004-06-14
SI2266573T1 (sl) 2015-08-31
JP3713237B2 (ja) 2005-11-09
IS2932B (is) 2015-12-15
TWI259086B (en) 2006-08-01
PT2266573E (pt) 2015-07-28
CZ304689B6 (cs) 2014-09-03
CH696260A5 (de) 2007-03-15
NO20150741L (no) 2002-07-03
AR027510A1 (es) 2003-04-02
ES2248272T5 (es) 2015-08-19
ITTO20010008A1 (it) 2002-07-10
CA2351004C (en) 2003-02-18
HK1049286B (en) 2006-04-07
ES2543384T3 (es) 2015-08-18
IL150230A0 (en) 2002-12-01
DK1250138T4 (en) 2015-07-27
MXPA02006698A (es) 2002-09-30
HUP0204137A2 (hu) 2003-04-28
JP2004107353A (ja) 2004-04-08
EE05421B1 (et) 2011-06-15
EP2286818A1 (en) 2011-02-23
NL1017075C2 (nl) 2001-09-25
UA75879C2 (en) 2006-06-15
FR2803516B1 (fr) 2003-03-28
EP1669073A3 (en) 2008-03-19
PL202525B1 (pl) 2009-07-31
NO336286B1 (no) 2015-07-13
HK1052884A1 (en) 2003-10-03
AU2386301A (en) 2001-07-24
HK1150021A1 (en) 2011-10-28
CZ20022384A3 (cs) 2002-09-11
GB0100407D0 (en) 2001-02-21
DE60114145T2 (de) 2006-07-13
EP1250138A1 (en) 2002-10-23
EP2286818B1 (en) 2020-03-18
DE60114145D1 (de) 2006-03-02
EP1669073A2 (en) 2006-06-14
DE10100779A1 (de) 2001-07-26
US8329680B2 (en) 2012-12-11
PT102548A (pt) 2001-07-31
CY1116520T1 (el) 2017-03-15
EP1250138B1 (en) 2005-10-19
NO337329B1 (no) 2016-03-14
US20050043285A1 (en) 2005-02-24
US20100152149A1 (en) 2010-06-17
NO20023227D0 (no) 2002-07-03
CO5280206A1 (es) 2003-05-30
CN1222292C (zh) 2005-10-12
IL150230A (en) 2006-10-31
BE1013477A3 (fr) 2002-02-05
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
RU2263507C2 (ru) 2005-11-10

Similar Documents

Publication Publication Date Title
GB2359254B (en) Formulation
GB0000891D0 (en) Formulation
EG24226A (en) Formulation
GB0021303D0 (en) Use
GB0015490D0 (en) Novel formulations
GB0025788D0 (en) Use
GB9902304D0 (en) Formulation
GB9905898D0 (en) Controlled-dose formulation
IL154258A0 (en) Fungicidal formulation
GB0125492D0 (en) Formulation
GB9927614D0 (en) Sterliant formulation
GB0005070D0 (en) Use
GB0029634D0 (en) Use
GB2396812B (en) Formulation
GB2375048B (en) Formulation
GB0116619D0 (en) Formulation
GB0004124D0 (en) Formulation
GB0010846D0 (en) Formulation
GB0023069D0 (en) Formulation
GB0001144D0 (en) Glysophosate formulation
GB0007112D0 (en) Formulation
GB0112497D0 (en) Formulation
GB9902236D0 (en) Formulation
GB0022027D0 (en) Disfectant formulations
GB9923538D0 (en) Formulation

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application
AT Applications terminated before publication under section 16(1)